Fate Therapeutics, Inc. (FATE) News
Follow Fate Therapeutics, Inc. (FATE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Fate Therapeutics Q3 Net Loss Narrows as Expenses Fall
EQUITY | Nov 05, 2026, 12:29 PM UTC
M
Fate Therapeutics Reports 3Q 2026 Revenue of $0 and EPS of ($0.25)
The company reported no collaboration revenue, compared with revenue a year earlier, after completing performance obligations under its Ono agreement in June. Net loss narrowed as lower research and administrative expens
EARNINGS | Nov 05, 2026, 12:13 PM UTC
M
Fate Therapeutics Reports Third-Quarter 2026 Results and Business Updates
The company reported third-quarter 2026 financial results and business updates. The body says a safety profile was presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single [truncated].
EQUITY | Nov 05, 2026, 12:02 PM UTC
M
Fate Therapeutics Q3 Results Expected October 29
Fate Therapeutics is scheduled to report Q3'26 results on October 29; the time is unspecified. Revenue is estimated at 1.14 million USD and EPS at (0.27) USD.
EQUITY | Oct 28, 2026, 11:04 AM UTC
L
Fate awarded $15M CIRM CLIN2 grant to fund Phase 2 RECLAIM-LN trial of FT819
Fate received a $15.0 million CIRM CLIN2 grant to support its Phase 2 RECLAIM-LN trial of FT819.Key Highlights:Original SEC Filing: FATE THERAPEUTICS INC [ FATE ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It ma
REGULATION | Sep 28, 2026, 12:16 PM UTC
L
Fate Therapeutics, Inc. (FATE) Wins $15M CIRM Grant for FT819 Phase 2 RECLAIM-LN
Fate Therapeutics received a $15.0M CIRM CLIN2 grant to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T in refractory SLE with lupus nephritis.Material DetailsContext by AI Ana
NEWS | Sep 25, 2026, 11:01 AM UTC
L
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive award from CIRM to fund
NEWS | Sep 25, 2026, 11:01 AM UTC
L
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
NEWS | Sep 16, 2026, 11:00 AM UTC
M
FATE’s scalable CAR T platform shows promising Phase II lupus nephritis progress
Conference update from FATE highlights a scalable, cost-effective CAR T platform, with Phase II underway for FT819 in lupus nephritis and early results aimed at 30%-40% CRR.
EQUITY | Sep 09, 2026, 03:05 PM UTC
L
FATE’s FT819 CAR T shows promising early lupus nephritis efficacy
Fate’s phase II trial of FT819 in lupus nephritis is progressing, supported by a scalable master cell bank approach. The program targets a 30%-40% CRR, with key data readouts expected by early next year.
EQUITY | Sep 09, 2026, 02:41 PM UTC
L
Fate Therapeutics to present FT819 Encore clinical data at CCR West 2026
Fate Therapeutics said it will present encore clinical data for its FT819 off-the-shelf CAR T-cell product candidate at the CCR West 2026 meeting.
EQUITY | Sep 09, 2026, 11:01 AM UTC
L
Fate Therapeutics to join fireside chat at Cantor Global Healthcare 2026
Fate Therapeutics says it will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference.
EQUITY | Sep 03, 2026, 11:00 AM UTC
M
Fate Therapeutics starts potentially registrational RECLAIM-LN FT819 trial
Fate Therapeutics (FATE) initiates the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis.
EQUITY | Aug 14, 2026, 11:00 AM UTC
L
Fate Therapeutics reports Q2 2026 financial results and business updates
Fate Therapeutics (FATE) reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:31 PM UTC
L
Fate Therapeutics Reports New Employee Awards
Fate Therapeutics grants new employee inducement awards
EQUITY | Aug 03, 2026, 08:05 PM UTC
H
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE: PXED ) fell sharply in pre-market trading after the
EARNINGS | Jul 15, 2026, 12:02 PM UTC
L
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
() -- (Updates to add the latest stock move in the headline and the first paragraph.) Fate Therapeutics (FATE) shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the compan
REGULATION | Jul 09, 2026, 06:48 PM UTC
L
Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company's next-generation, off-the-shelf CAR T-cell product candidate engineered to co-target CD19 and
EQUITY | Jul 09, 2026, 01:25 PM UTC
L
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISS
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
EQUITY | Jul 06, 2026, 12:30 PM UTC